Arcturus Therapeutics Holdings (ARCT) Accumulated Expenses (2018 - 2026)

Arcturus Therapeutics Holdings has reported Accumulated Expenses for 9 years, with the latest figure at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 13.6% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (down 13.6% YoY), and the FY2025 full-year result was $23.9 million, down 38.38% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.5 million, down from $23.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $38.8 million in Q4 2024, with the low at $4.0 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $17.0 million across 5 years, with a median of $9.2 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 85.1% — and 2024, when it jumped 555.31%.
• Arcturus Therapeutics Holdings' Accumulated Expenses stood at $4.0 million in 2022, then surged by 46.56% to $5.9 million in 2023, then jumped by 555.31% to $38.8 million in 2024, then sank by 38.38% to $23.9 million in 2025, then sank by 77.02% to $5.5 million in 2026.
• The last three Accumulated Expenses figures came in at $5.5 million (Q1 2026), $23.9 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.